Lakefront Biotherapeutics American Depositary Shares
LKFT
141 hedge funds and large institutions have $1.5B invested in Lakefront Biotherapeutics American Depositary Shares in 2020 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 47 increasing their positions, 48 reducing their positions, and 23 closing their positions.
179% more call options, than puts
Call options by funds: $90.7M | Put options by funds: $32.5M
30% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 23
3% more funds holding
Funds holding: 137 → 141 (+4)
0.13% more ownership
Funds ownership: 11.69% → 11.82% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 48
4% less capital invested
Capital invested by funds: $1.56B → $1.5B (-$56.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$154M |
| 2 |
Renaissance Technologies
New York
|
+$50.3M |
| 3 |
Citigroup
New York
|
+$21.5M |
| 4 |
Morgan Stanley
New York
|
+$10.6M |
| 5 |
BlackRock
New York
|
+$6.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$89M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$35.7M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$28M |
| 4 |
Jane Street
New York
|
-$18.2M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$13.6M |
LKFT Hedge Fund Activity: Q1 2020 in Review
141 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2020, worth a combined $1.5B — down 3.6% from $1.56B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new LKFT positions and 23 closed out — a net gain of 7 holders — while 47 added to existing stakes and 48 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $154M. The largest seller was Sands Capital Management, cutting an estimated $89M.
- 141 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2020, up from 137 in Q4 2019.
- Funds reported $1.5B of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2020, down 3.6% quarter-over-quarter.
- 30 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2020 and 23 closed out, a net change of +7 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2020 was Fidelity Investments, an estimated $154M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2020 was Sands Capital Management, an estimated $89M sold.
Based on aggregated 13F filings for Q1 2020.